ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm. We are focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations with field-deployable versions for biodefense and military.
ExThera Medical Corporation is a privately held Delaware C corporation with a focus in the development and commercialization of innovative device-based clinical treatments for both drug-resistant and drug-susceptible bloodstream infections.
ExThera Medical is currently in a capital growth phase. Please contact the following to learn more about our current investment programs:
Greg Dollarhyde | Director
Michael Benjamin | Vice President of Accounting
ExThera Medical Corporation